title: Short-time mitomycin-C application during photorefractive keratectomy in patients with low myopia.
abstract: OBJECTIVE
  To evaluate the safety and efficacy of 5 seconds of mitomycin-C (MMC) application during photorefractive keratectomy (PRK) for low myopia.
  
  
  METHODS
  Basir Eye Clinic, Tehran, Iran.
  
  
  METHODS
  Prospective randomized sham-controlled double-masked clinical trial.
  
  
  METHODS
  Patients with low myopia and an ablation depth of less than 65 μm were recruited. One eye of each patient was included in the study and was randomly assigned to receive intraoperative topical MMC 0.02% for 5 seconds or a balanced salt solution in the same manner (control group). Corneal haze development during the 6 months after the PRK was the main outcome measure.
  
  
  RESULTS
  Of the 184 eligible patients (MMC = 93; control = 91), 152 (78 and 74, respectively) completed the follow-up. The postoperative haze grade was significantly lower in the MMC group (P=.01). The mean endothelial cell density was not significantly different between the MMC group and the control group preoperatively (2879.97 cells/mm(2) ± 298.04 [SD] versus 2819.69 ± 303.89 cells/mm(2); P=.22) or 6 months postoperatively (2878.79 ± 283.04 cells/mm(2) versus 2878.79 ± 283.04 cells/mm(2); P=.25). No notable ocular complication occurred throughout the study.
  
  
  CONCLUSIONS
  Short-time application of MMC 0.02% was safe and effective in preventing haze formation in eyes having PRK with an ablation depth of less than 65 μm compared with matched controls up to 6 months.
  
  
  BACKGROUND
  No author has a financial or proprietary interest in any material or method mentioned.
authors.affiliation: Basir Eye Center, Tehran, Iran.
authors.forename: Ahmad
authors.initials: A
authors.lastname: Shojaei
authors.forename: Mohsen
authors.initials: M
authors.lastname: Ramezanzadeh
authors.forename: Saeed
authors.initials: S
authors.lastname: Soleyman-Jahi
authors.forename: Mina
authors.initials: M
authors.lastname: Almasi-Nasrabadi
authors.forename: Parisa
authors.initials: P
authors.lastname: Rezazadeh
authors.forename: Medi
authors.initials: M
authors.lastname: Eslani
mesh_terms: D000328:Adult; D000477:Alkylating Agents / Q000008:administration & dosage* / Q000009:adverse effects; D002452:Cell Count; D003315:Cornea / Q000187:drug effects*; D003318:Corneal Opacity / Q000517:prevention & control*; D004311:Double-Blind Method; D004728:Endothelium, Corneal / Q000473:pathology; D005260:Female; D006801:Humans; D007432:Intraoperative Period; D054018:Lasers, Excimer / Q000627:therapeutic use*; D008297:Male; D016685:Mitomycin / Q000008:administration & dosage* / Q000009:adverse effects; D009216:Myopia / Q000601:surgery*; D009883:Ophthalmic Solutions; D018903:Photorefractive Keratectomy; D011446:Prospective Studies; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D000477:Alkylating Agents; D009883:Ophthalmic Solutions; D016685:Mitomycin